Anagrelide
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-ANAGRELIDE |
|---|---|
| Type | Drug |
| Aliases | AgrylinXagridАнагрелід |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | DIS-ET DIS-PV |
| Sources | SRC-ESMO-MPN-2015 SRC-NCCN-MPN-2025 |
Drug Facts
| Class | Phosphodiesterase-3 inhibitor (selective platelet-reduction) |
|---|---|
| Mechanism | Selectively reduces platelet count by interfering with megakaryocyte differentiation. Does not lower WBC or Hct (unlike HU). Used as 2L cytoreduction in ET when HU is intolerated or insufficient. |
| Typical dosing | ET: start 0.5 mg PO BID; titrate by 0.5 mg/day weekly to plt <600K (target plt <400-450K). Maximum 10 mg/day; usual maintenance 1-3 mg/day divided. |
| Ukraine registered | True |
| NSZU reimbursed | False |
| Ukraine last verified | 2026-04-27 |
Warnings
- Cardiovascular events — vasodilation, palpitations, heart failure (use with caution in cardiac comorbidity)
Notes
ET 2L per PT-1 trial (Harrison et al., NEJM 2005): non-inferior to HU on thrombosis but more arterial thrombosis + bleeding + myelofibrosis progression in some endpoints. Reserved for HU-intolerance/resistance or for younger ET patients wanting to avoid HU's theoretical leukemogenic concern. Cardiac evaluation (ECG ± echo) recommended before starting if comorbidity present.
Used By
Regimens
REG-ANAGRELIDE-ET- Anagrelide — ET 2L cytoreduction (HU-intolerant / HU-resistant)